After its latest pipeline clear-out, Merck KGaA is no longer pursuing any clinical-stage cancer candidates obtained through ...

Merck KGaA (ETR:MRK) executives told investors the company delivered “solid” organic growth in 2025 despite a challenging ...

Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of 2.7%. Here, we discuss the reasons for the same. Strong Launch of SWTX's ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

6 analysts have expressed a variety of opinions on SpringWorks Therapeutics (NASDAQ:SWTX) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...

Reacting to press speculation, Merck KGaA has acknowledged that talks to buy US biotech SpringWorks are now in the late stages and are revolving around an offer of around $47 per share. Merck stressed ...

Investors with a lot of money to spend have taken a bearish stance on SpringWorks Therapeutics (NASDAQ:SWTX). And retail traders should know. We noticed this today when the trades showed up on ...

SpringWorks Therapeutics is launching a new disease state education campaign at DesmoidTumors.com. The clinical-stage biotech, which is working on medicines to help patients suffering from rare ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease drugmaker has attracted the attention of a biopharma bigwig from overseas.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. After months of discussion, Germany’s Merck KGaA said Monday it would buy ...

A SpringWorks Therapeutics drug has won FDA approval for treating a rare connective tissue tumor, making it the first approved therapy for this type of tumor. It’s also the first product approval for ...

Pfizer spin-out SpringWorks Therapeutics has its first approved product after getting a green light from the FDA for Ogsiveo, the first-ever therapy for a rare type of non-cancerous tumour that can ...